Search clinical trials for: IMDEVIMAB

Total 24 results

Regeneron Pharmaceuticals

Completed

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

Healthy | Chronic Stable Illness

United States
Regeneron Pharmaceuticals

Terminated

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

SARS-CoV-2

United States
University of Ulm

Completed

Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application (CasiTocCOVID)

COVID-19 | Critically Ill | Outcome, Fatal | Interleukin 6 | Tocilizumab

Germany
Regeneron Pharmaceuticals

No longer available

Compassionate Use of REGN-COV2 for the Treatment of COVID-19

COVID-19
Regeneron Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

COVID-19

United States, Mexico, Romania
Regeneron Pharmaceuticals

Terminated

A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

Immunocompromised

United States, Mexico
Erin McCreary
University of Pittsburgh

Terminated

UPMC OPTIMISE-C19 Trial, a COVID-19 Study (OPTIMISE-C19)

Covid19

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...

Recruiting

TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2 (TURN-COVID)

COVID-19

Netherlands
Regeneron Pharmaceuticals

Completed

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Healthy Participants

United States, Moldova, Republic of, Romania
Regeneron Pharmaceuticals

Completed

COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

COVID-19

United States
Regeneron Pharmaceuticals

Terminated

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

COVID-19

United States
Sohail Rao

Recruiting

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

Covid19

United States
Regeneron Pharmaceuticals

Terminated

COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19

COVID-19

United States
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

COVID-19

United States, Mexico, Romania, Brazil, Chile, Moldova, Republic of
Mansoura University Hospital

Completed

Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients

COVID-19

Egypt
Regeneron Pharmaceuticals

Completed

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

Healthy | Chronic Stable Illness

United States
Regeneron Pharmaceuticals

Completed

COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

Healthy | Chronic Stable Illness

United States
Northwell Health
Regeneron Pharmaceuticals

Withdrawn

Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail

COVID-19 | Organ Transplant

United States
Azienda Ospedaliera Universitaria Integrata Verona
Agenzia Italiana del Farmaco; Azienda Sanitaria-Universitaria Integrata di...

Terminated

Non-inferiority Trial on Monoclonal Antibodies in COVID-19 (MANTICO)

COVID-19

Italy
University of Milano Bicocca

Recruiting

COVID-19 and Disease Progression to the Severe Form: A Study on the Use of Monoclonal Antibodies Against SARS-CoV-2 (CONDIVIDIAMO)

COVID-19

Italy
Pregistry

Recruiting

COVID-19 International Drug Pregnancy Registry (COVID-PR)

Covid19

United States
University of Calgary
Sunnybrook Research Institute

Terminated

Treatment of Nosocomial COVID-19 (CATCO-NOS)

Covid19 | SARS-CoV2 Infection | Nosocomial Infection

Canada
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AIDS Clinical Trials... and other collaborators

Completed

ACTIV-2: A Study for Outpatients With COVID-19

Covid19 | Coronavirus

United States, Argentina, Brazil, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, Canada
University of Oxford
Bill and Melinda Gates Foundation; Department for International Development... and other collaborators

Recruiting

Randomised Evaluation of COVID-19 Therapy (RECOVERY)

Severe Acute Respiratory Syndrome

Ghana, Indonesia, Nepal, South Africa, United Kingdom, Vietnam, India

3

Subscribe